Reflections on the AMBASSADOR trial: The role of adjuvant pembrolizumab in muscle-invasive urothelial carcinoma.

IF 11.7 1区 医学 Q1 CELL BIOLOGY Cell Reports Medicine Pub Date : 2024-12-17 DOI:10.1016/j.xcrm.2024.101873
Pietro Scilipoti, Marco Moschini, Alberto Briganti
{"title":"Reflections on the AMBASSADOR trial: The role of adjuvant pembrolizumab in muscle-invasive urothelial carcinoma.","authors":"Pietro Scilipoti, Marco Moschini, Alberto Briganti","doi":"10.1016/j.xcrm.2024.101873","DOIUrl":null,"url":null,"abstract":"<p><p>Recent advances in immunotherapy have transformed treatment for muscle-invasive urothelial carcinoma, providing hope for cisplatin-ineligible patients. The AMBASSADOR trial evaluated adjuvant pembrolizumab in high-risk patients post-surgery, demonstrating improved disease-free survival. As overall survival data evolve, pembrolizumab is emerging as a promising adjuvant treatment option, complementing existing therapies in the treatment landscape for this disease.</p>","PeriodicalId":9822,"journal":{"name":"Cell Reports Medicine","volume":"5 12","pages":"101873"},"PeriodicalIF":11.7000,"publicationDate":"2024-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11722087/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cell Reports Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.xcrm.2024.101873","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CELL BIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Recent advances in immunotherapy have transformed treatment for muscle-invasive urothelial carcinoma, providing hope for cisplatin-ineligible patients. The AMBASSADOR trial evaluated adjuvant pembrolizumab in high-risk patients post-surgery, demonstrating improved disease-free survival. As overall survival data evolve, pembrolizumab is emerging as a promising adjuvant treatment option, complementing existing therapies in the treatment landscape for this disease.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
对AMBASSADOR试验的反思:辅助派姆单抗在肌肉侵袭性尿路上皮癌中的作用
免疫疗法的最新进展已经改变了肌肉侵袭性尿路上皮癌的治疗方法,为不适合顺铂治疗的患者提供了希望。AMBASSADOR试验评估了高风险患者术后的辅助派姆单抗,显示出无病生存期的改善。随着总体生存数据的发展,派姆单抗正成为一种有希望的辅助治疗选择,补充了该疾病治疗领域的现有疗法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Cell Reports Medicine
Cell Reports Medicine Biochemistry, Genetics and Molecular Biology-Biochemistry, Genetics and Molecular Biology (all)
CiteScore
15.00
自引率
1.40%
发文量
231
审稿时长
40 days
期刊介绍: Cell Reports Medicine is an esteemed open-access journal by Cell Press that publishes groundbreaking research in translational and clinical biomedical sciences, influencing human health and medicine. Our journal ensures wide visibility and accessibility, reaching scientists and clinicians across various medical disciplines. We publish original research that spans from intriguing human biology concepts to all aspects of clinical work. We encourage submissions that introduce innovative ideas, forging new paths in clinical research and practice. We also welcome studies that provide vital information, enhancing our understanding of current standards of care in diagnosis, treatment, and prognosis. This encompasses translational studies, clinical trials (including long-term follow-ups), genomics, biomarker discovery, and technological advancements that contribute to diagnostics, treatment, and healthcare. Additionally, studies based on vertebrate model organisms are within the scope of the journal, as long as they directly relate to human health and disease.
期刊最新文献
Lurbinectedin sensitizes PD-L1 blockade therapy by activating STING-IFN signaling in small-cell lung cancer. Targeting the mevalonate pathway potentiates NUAK1 inhibition-induced immunogenic cell death and antitumor immunity. MFGE8 induces anti-PD-1 therapy resistance by promoting extracellular vesicle sorting of PD-L1. A genome-wide association study identified PRKCB as a causal gene and therapeutic target for Mycobacterium avium complex disease. Multimodal integration using a machine learning approach facilitates risk stratification in HR+/HER2- breast cancer.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1